Log on / register
Feedback | Support | My details
Open AccessHighly AccessResearch article

UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review

Frank Breuckmann1 email, Thilo Gambichler2 email, Peter Altmeyer1 email and Alexander Kreuter1 email

1Department of Dermatology, Ruhr-University Bochum, 44791 Bochum, Germany

2Dermatology Out-Patient Clinic, Oldchurch Hospital, Romford RM7 OBE, Greater London, UK

author email corresponding author email

BMC Dermatology 2004, 4:11doi:10.1186/1471-5945-4-11

Published: 20 September 2004

Abstract

Background

Broad-band UVA, long-wave UVA1 and PUVA treatment have been described as an alternative/adjunct therapeutic option in a number of inflammatory and malignant skin diseases. Nevertheless, controlled studies investigating the efficacy of UVA irradiation in connective tissue diseases and related disorders are rare.

Methods

Searching the PubMed database the current article systematically reviews established and innovative therapeutic approaches of broad-band UVA irradiation, UVA1 phototherapy and PUVA photochemotherapy in a variety of different connective tissue disorders.

Results

Potential pathways include immunomodulation of inflammation, induction of collagenases and initiation of apoptosis. Even though holding the risk of carcinogenesis, photoaging or UV-induced exacerbation, UVA phototherapy seems to exhibit a tolerable risk/benefit ratio at least in systemic sclerosis, localized scleroderma, extragenital lichen sclerosus et atrophicus, sclerodermoid graft-versus-host disease, lupus erythematosus and a number of sclerotic rarities.

Conclusions

Based on the data retrieved from the literature, therapeutic UVA exposure seems to be effective in connective tissue diseases and related disorders. However, more controlled investigations are needed in order to establish a clear-cut catalogue of indications.


© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.